Department of Pathology, Homi Bhabha Cancer Hospital and Research Centre, Punjab (A Unit of Tata Memorial Centre), India.
Department of Radiotherapy, Homi Bhabha Cancer Hospital and Research Centre, Punjab (A Unit of Tata Memorial Centre), India.
J Cancer Res Ther. 2021 Apr-Jun;17(2):551-555. doi: 10.4103/jcrt.JCRT_613_20.
The coronavirus disease 2019 (COVID 19) is a zoonotic viral infection that originated in Wuhan, China, in December 2019. It was declared a pandemic by the World Health Organization shortly thereafter. This pandemic is going to have a lasting impact on the functioning of pathology laboratories due to the frequent handling of potentially infectious samples by the laboratory personnel. To deal with this unprecedented situation, various national and international guidelines have been put forward outlining the precautions to be taken during sample processing from a potentially infectious patient.
Most of these guidelines are centered around laboratories that are a part of designated COVID 19 hospitals. However, proper protocols need to be in place in all laboratories, irrespective of whether they are a part of COVID 19 hospital or not as this would greatly reduce the risk of exposure of laboratory/hospital personnel. As part of a laboratory associated with a rural cancer hospital which is not a dedicated COVID 19 hospital, we aim to present our institute's experience in handling pathology specimens during the COVID 19 era.
We hope this will address the concerns of small to medium sized laboratories and help them build an effective strategy required for protecting the laboratory personnel from risk of exposure and also ensure smooth and optimum functioning of the laboratory services.
2019 年冠状病毒病(COVID-19)是一种源自中国武汉的人畜共患病毒性感染。世界卫生组织随后不久宣布该疾病为大流行。由于实验室人员经常处理潜在传染性样本,这种大流行将对病理实验室的功能产生持久影响。为了应对这种前所未有的情况,已经提出了各种国家和国际指南,概述了在处理来自潜在传染性患者的样本时应采取的预防措施。
这些指南大多集中在作为指定 COVID-19 医院一部分的实验室。然而,所有实验室都需要制定适当的协议,无论它们是否是 COVID-19 医院的一部分,因为这将大大降低实验室/医院人员暴露的风险。作为一家与农村癌症医院相关的实验室,该医院不是专门的 COVID-19 医院,我们旨在介绍我们机构在 COVID-19 期间处理病理标本的经验。
我们希望这将解决中小型实验室的关注,并帮助他们制定保护实验室人员免受暴露风险所需的有效策略,并确保实验室服务的顺利和最佳运作。